PharmaPendium’s Metabolizing Enzymes module offers a new major resource for the modelling of adverse drug interactions resulting from effects of drug-metabolizing enzymes and transporters.
It stands as a unique content source for preclinical researchers, unmatched in terms of depth of data on CYPs, Phase 2 enzymes, transporters and dynamic pharmacokinetic parameters. Interactions between drugs, enzymes and transporters are provided with the drug’s role as substrate, inhibitor, or inducer listed to give a clear and immediate overview.
The PharmaPendium Metabolizing Enzymes Module is an essential resource in understanding drug-drug interactions that lead to unintended/unanticipated Toxicity and Efficacy failures.
The addition of the Metabolizing Enzymes Module to PharmaPendium’s best in class content on drug safety and Pharmacokinetics (PK Module) provides a more complete resource for preclinical drug assessment, allowing drug development teams to identify potential problems earlier and reduce the frequency of late stage failures.